Summary
UnitedHealthcare Community Plan of Kentucky updated its Ilaris (canakinumab) medical benefit drug policy for Medicaid members in Kentucky, effective 2026-12-01. For Active Still's Disease, including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA), the coverage rationale now states that the patient must not be receiving Ilaris in combination with another systemic targeted immunomodulator for the same indication.
Get alerts when payers change rules like this one
We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.
Get UnitedHealthcare alertsPolicy Monitoring is free. No card required.
What to do
Action · 4 steps
01By 2026-12-01: Billing team and providers should confirm, before scheduling or billing Ilaris for Kentucky Community Plan Medicaid members with Active Still's Disease (AOSD or SJIA), that the member is not concurrently receiving another systemic targeted immunomodulator for the same indication, and document this in the prior authorization request and chart.
02Update the prior authorization tracker and charge entry workflow so that Ilaris claims for these members include supporting documentation of the concurrent therapy review.
03Tell providers and front desk staff about the added combination-therapy language so requests are submitted with accurate medication history.
04Watch for the payer's updated policy text and clinical references, which were also revised in this bulletin.
Original notice
Ilaris ® (Canakinumab)
uhcprovider.com · Always check the source before changing claims.
Related changes
See all UnitedHealthcare changes →Ilaris ® (Canakinumab)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyIlaris® (Canakinumab)LowEffective Dec 1, 2026 · Medical PolicyIlaris ® (Canakinumab)LowEffective Dec 1, 2026 · Medical Benefit Drug PolicyIlaris ® (Canakinumab)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyBrowse every UnitedHealthcare change in the policy list